Guerbet (ENXTPA:GBT) - Share price, News & Analysis

GBT fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	5/6
Dividends	4/6

GBT Stock Overview

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

Rewards

Trading at 59.5% below our estimate of its fair value

Earnings are forecast to grow 8.56% per year

Earnings grew by 84% over the past year

Pays a reliable dividend of 3.42%

Risk Analysis

Has a high level of debt

Guerbet Competitors

Abbott Laboratories

NYSE:ABT

US$201.1b

Medtronic

NYSE:MDT

US$133.4b

Becton Dickinson

NYSE:BDX

US$72.0b

Edwards Lifesciences

NYSE:EW

US$61.3b

Price History & Performance

Summary of all time highs, changes and price drops for Guerbet
Historical stock prices
Current Share Price	€24.85
52 Week High	€45.65
52 Week Low	€22.55
Beta	0.77
1 Month Change	0.61%
3 Month Change	-16.75%
1 Year Change	-21.73%
3 Year Change	-48.07%
5 Year Change	-70.02%
Change since IPO	150.14%

Recent News & Updates

Mar 28

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Guerbet SA ( EPA:GBT ) shareholders are probably feeling a little disappointed, since its shares fell 9.1% to €26.50 in...

Oct 25

Is Guerbet (EPA:GBT) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

	GBT	FR Medical Equipment	FR Market
7D	3.5%	4.4%	-1.1%
1Y	-21.7%	-5.8%	-5.9%

Return vs Industry: GBT underperformed the French Medical Equipment industry which returned -5.8% over the past year.

Return vs Market: GBT underperformed the French Market which returned -5.9% over the past year.

Price Volatility

Is GBT's price volatile compared to industry and market?
GBT volatility
GBT Average Weekly Movement	5.1%
Medical Equipment Industry Average Movement	7.0%
Market Average Movement	5.9%
10% most volatile stocks in FR Market	10.0%
10% least volatile stocks in FR Market	3.4%

Stable Share Price: GBT is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: GBT's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1926	2,635	David Hale	https://www.guerbet.com

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate; Conray, an othalamate meglumine injection; and Micropaque/ Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem products, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain that offers cloud-based AI solutions, as well as OptiProtect services.

Guerbet Fundamentals Summary

How do Guerbet's earnings and revenue compare to its market cap?
GBT fundamental statistics
Market Cap	€313.01m
Earnings (TTM)	€32.60m
Revenue (TTM)	€737.00m

9.6x

P/E Ratio

0.4x

P/S Ratio

Is GBT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GBT income statement (TTM)
Revenue	€737.00m
Cost of Revenue	€190.90m
Gross Profit	€546.10m
Other Expenses	€513.50m
Earnings	€32.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 21, 2022

Earnings per share (EPS)	2.59
Gross Margin	74.10%
Net Profit Margin	4.42%
Debt/Equity Ratio	82.5%

How did GBT perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

32%

Payout Ratio

Does GBT pay a reliable dividends?

See GBT dividend history and benchmarks

When do you need to buy GBT by to receive an upcoming dividend?
Guerbet dividend dates
Ex Dividend Date	Jun 29 2022
Dividend Pay Date	Jul 01 2022
Days until Ex dividend	33 days
Days until Dividend pay date	35 days

Does GBT pay a reliable dividends?

See GBT dividend history and benchmarks

Valuation

Is Guerbet undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: GBT (€24.85) is trading below our estimate of fair value (€61.33)

Significantly Below Fair Value: GBT is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: GBT is good value based on its Price-To-Earnings Ratio (9.6x) compared to the French Medical Equipment industry average (13.7x).

PE vs Market: GBT is good value based on its Price-To-Earnings Ratio (9.6x) compared to the French market (16.2x).

Price to Earnings Growth Ratio

PEG Ratio: GBT is poor value based on its PEG Ratio (1.1x)

Price to Book Ratio

PB vs Industry: GBT is good value based on its Price-To-Book Ratio (0.8x) compared to the FR Medical Equipment industry average (2.2x).

Future Growth

How is Guerbet forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

8.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GBT's forecast earnings growth (8.6% per year) is above the savings rate (0.3%).

Earnings vs Market: GBT's earnings (8.6% per year) are forecast to grow slower than the French market (11.9% per year).

High Growth Earnings: GBT's earnings are forecast to grow, but not significantly.

Revenue vs Market: GBT's revenue (4.7% per year) is forecast to grow slower than the French market (5.8% per year).

High Growth Revenue: GBT's revenue (4.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GBT's Return on Equity is forecast to be low in 3 years time (9.4%).

Past Performance

How has Guerbet performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-8.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GBT has high quality earnings.

Growing Profit Margin: GBT's current net profit margins (4.4%) are higher than last year (2.5%).

Past Earnings Growth Analysis

Earnings Trend: GBT's earnings have declined by 8.4% per year over the past 5 years.

Accelerating Growth: GBT's earnings growth over the past year (84%) exceeds its 5-year average (-8.4% per year).

Earnings vs Industry: GBT earnings growth over the past year (84%) exceeded the Medical Equipment industry 22.5%.

Return on Equity

High ROE: GBT's Return on Equity (8%) is considered low.

Financial Health

How is Guerbet's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: GBT's short term assets (€496.0M) exceed its short term liabilities (€237.0M).

Long Term Liabilities: GBT's short term assets (€496.0M) exceed its long term liabilities (€359.0M).

Debt to Equity History and Analysis

Debt Level: GBT's net debt to equity ratio (53.8%) is considered high.

Reducing Debt: GBT's debt to equity ratio has reduced from 125.6% to 82.5% over the past 5 years.

Debt Coverage: GBT's debt is well covered by operating cash flow (30.8%).

Interest Coverage: GBT's interest payments on its debt are well covered by EBIT (14x coverage).

Balance Sheet

Dividend

What is Guerbet current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

3.42%

Current Dividend Yield

Upcoming Dividend Payment

Dividend Yield vs Market

Notable Dividend: GBT's dividend (3.42%) is higher than the bottom 25% of dividend payers in the French market (1.72%).

High Dividend: GBT's dividend (3.42%) is low compared to the top 25% of dividend payers in the French market (5.01%).

Stability and Growth of Payments

Stable Dividend: GBT's dividends per share have been stable in the past 10 years.

Growing Dividend: GBT's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (32.5%), GBT's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Insufficient data to calculate cash payout ratio to determine if its dividend payments are covered by cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure

CEO

David Hale (53 yo)

2.33yrs

Tenure

€932,678

Compensation

Mr. David Hale has been Chief Executive Officer of Guerbet SA since January 1, 2020 and serves as its MD & GM. Mr. Hale served as Chief Commercial Officer of Guerbet SA since 2019 until January 1, 2020 and...

CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD1.00M) is above average for companies of similar size in the French market ($USD479.65K).

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.

Leadership Team

Experienced Management: GBT's management team is considered experienced (2.3 years average tenure).

Board Members

Experienced Board: GBT's board of directors are considered experienced (6 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/26 00:00
End of Day Share Price	2022/05/26 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31